Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 770

Toronto plans new innovation complex

The university will benefit from a hub to house its AI and biomedical research in addition to co-working space and a think-tank targeting the ethics of emerging technologies.

Mar 26, 2019

Toronto to dedicate $1.9m to True Blue Fund

The vehicle has a target size of $3.7m to be fulfilled by donations from philanthropists, with the aim of providing support to early-stage university businesses and research.

Mar 26, 2019

EMV Capital rescues Vortex and Wanda

NetScientific has exited its loss-making portfolio companies Vortex and Wanda after originally deciding to close the two medical diagnostics ventures last week.

Mar 26, 2019

GreenMark carves out $1.2m

GreenMark’s dental treatments will be developed in partnership with University of Michigan, which has backed the company’s two-tranche seed round through its Mints Fund.

Mar 26, 2019

McDonald’s to consume Dynamic Yield for more than $300m

Baidu, Deutsche Telekom, Naver, New York Times and ProSiebenSat.1 are all set to exit the machine learning software provider in an acquisition by McDonald’s.

Mar 26, 2019

Zoom comes face to face with $100m IPO

Profitable video conferencing technology provider Zoom has filed to go public, with Qualcomm Ventures set to record an exit.

Mar 26, 2019

Pfizer’s Jones to retire

Elaine Jones, vice-president at pharmaceutical company Pfizer’s corporate venture capital unit, has shared highlights of her career with GCV ahead of her departure in April.

Mar 26, 2019

Patterns for my success

Remarks made at Pfizer Women’s Breakfast at JP Morgan by Elaine Jones, vice-president of Pfizer Ventures, in January 2019.

Mar 26, 2019

Skedulo closes book on $28m series B

The employee management platform developer has completed an M12-led round that took its overall funding past the $40m mark and will use the cash for hiring.

Mar 26, 2019

Imago marks series B round with $40m

Amgen Ventures, MRL Ventures Fund and Pharmaron contributed to a round that almost doubled the total raised by the bone marrow disease drug developer since 2012.

Mar 26, 2019
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here